Taking advantage of a mouse model of HL, Di Stasi et al. demonstrated that CAR-T cells engineered to co-express the chemokine receptor CCR4 together with the effector antigen receptor CD30 (CAR-CD30 T cells), had improved migration towards the tumor and enhanced anti-lymphoma activity as compared to CD30 CAR-T cells lacking CCR4 expression (49). The gene discussed is CCR4; the disease is neoplasm.